Immunogenicity and safety of a varicella vaccine, Okavax™, and a trivalent measles, mumps and rubella vaccine, MMR-II™, administered concomitantly in healthy Filipino children aged 12-24 months

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 34, Issue 3, 2003, Pages 589-597

  Gatchalian, Salvacion ^a,b,d   Leboulleux, Didier ^c   Desauziers, Eric ^c   Bermal, Nancy ^a,b   Borja Tabora, Charissa ^a,b  

^a Department of Health   (Philippines)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^c SANOFI PASTEUR   (France)

^d Department of Dermatology   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; MEASLES MUMPS RUBELLA VACCINE; MMR II; OKAVAX; TRIPLE VACCINE;

ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CHICKENPOX; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; MALE; MEASLES; MUMPS; NORMAL HUMAN; PAIN; PHILIPPINES; RANDOMIZED CONTROLLED TRIAL; RASH; RUBELLA; SEROCONVERSION; SIDE EFFECT; SKIN INDURATION; VACCINATION; VIRUS INFECTION;

EID: 0346339848     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. American Academy of Pediatrics (AAP): Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mumps-rubella vaccine. Pediatrics 1998; 101: 129-33.
2. Arguedas AG, Deveikis AA, Marks MI. Measles. Am J Infect Control 1991; 19: 290-8.
3. Arvin AM. Varicella vaccine-the first six years. N Engl J Med 2001; 344: 1007-9.
4. Berger R, Just M. Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccines. J Biol Stand 1988; 16: 275-9.
5. Breuer J. Vaccination to prevent varicella and shingles. J Clin Pathol 2001; 54: 743-7.
6. Carter H, Campbell H. Rational use of measles, mumps and rubella (MMR) vaccine. Drugs 1993; 45: 677-83.
7. Centers for Disease Control and Prevention (CDC). Mumps - United States, 1985-1988. Morb Mortal Wkly Rep 1989; 38: 101-5.
8. Centers for Disease Control and Prevention (CDC). Increase in rubella and congenital rubella syndrome - United States, 1988-1990. Morb Mortal Wkly Rep 1991; 40: 93-9.
9. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 1996; 45: 1-36.
10. Clements DA. Modified varicella-like syndrome. Infect Dis Clin North Am 1996; 10: 617-29.
11. Cutts FT, Henderson RH, Clements CJ, Chen RT, Patriarca PA. Principles of measles control. Bull WHO 1991; 69: 1-7.
12. rd ed. Philadelphia: WB Saunders, 1999: 508-18.
13. rd World Congress of Pediatric Infectious Diseases (WSPID). Nov 19-23, 2002.
14. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull WHO 1999; 77: 3-14.
15. Johnson CE, Stancin T, Fattlar D, Rome LP, Kumar ML. A long-term prospective study of varicella vaccine in healthy children. Pediatrics 1997; 100: 761-6.
16. Just M, Berger R, Just V. Evaluation of a combined measles-mumps-rubella- chickenpox vaccine. Dev Biol Stand 1986; 65: 85-8.
17. Meurice F, De Bouver J-L, Vandevoorde D, Woods S, Bogaerts H. Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. J Infect Dis 1996; 174 (suppl 3): S324-S9.
18. Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine 1995; 13: 799-802.
19. National Vaccine Advisory Committee. The measles epidemic. The problems, barriers and recommendations. JAMA 1991; 266: 1547-52.
20. Nokes, DJ, Anderson RM. Vaccine safety versus vaccine efficacy in mass immunisation programmes. Lancet 1991; 338: 1309-12.
21. Osaki T, Nishimura N, Kajita Y. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic. Vaccine 2000; 18: 2375-80.
22. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. Lancet 1986; i: 939-42.
23. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331: 1397-402.
24. Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. JAMA 2000; 284: 2643-7.
25. rd ed. Philadelphia: WB Saunders; 1999: 267-92.
26. Plotkin SA. Review. Rubella eradication. Vaccine 2001; 19: 3311-9.
27. rd ed. Philadelphia: WB Saunders; 1999: 222-50.
28. II and TETRAMUNE® followed six weeks later by VARIVAX®. Pediatr Infect Dis J 1998; 17: 980-5.
29. Takahashi M. 25 years' experience with the Biken Oka strain varicella vaccine. A clinical overview. Paediatr Drugs 2001; 3: 285-92.
30. Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R. Reactogenicity of a new live attenuated combined measles, mumps, rubella vaccine in healthy children. Pediatr Infect Dis J 1999; 18: 42-8.
31. Vesikari T, Ohrling A, Baer M, Delem A, Bogaerts H, Andre FE. Evaluation of live attenuated varicella vaccine (OKA-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children. Acta Paediatr Scand 1991; 80: 1051-7.
32. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). Recom Rep 1998; 47: 1-57.
33. IIV) in healthy children. J Infect Dis 1996; 173: 731-4.
34. White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (Varivax) in healthy children and adolescents: results from clinical trails, 1987 to 1989. Pediatrics 1991; 87: 604-10.
35. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992; 11: 19-23.
36. White CJ, Stinson D, Staehle B, et al. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Clin Infect Dis 1997; 24: 925-31.
37. World Health Organisation (WHO). Expanded Programme of Immunisation. Immunisation schedules in the WHO European region 1995. Wkly Epidemiol Rec 1995; 70: 221-7.
38. World Health Organisation (WHO). Varicella vaccines. WHO position paper. Wkly Epidemiol Rec 1998; 32: 241-8.
39. World Health Organisation (WHO). Measles. Progress towards global control and regional elimination, 1998-1999. Wkly Epidemiol Rec 1999; 50: 429-39.
40. Zerboni L, Nader S, Aoki K, Arvin AM. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis 1998; 177: 1701-4.